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ABSTRACT
Reduced intensity conditioning has been suggested as a desirable therapeutic modality for the treatment of
patients with malignant and nonmalignant indications, but it seems particularly attractive for patients with
Fanconi anemia due to their increased sensitivity to chemoradiotherapy. Between November 1996 and
September 2003, 7 patients (1 male and 6 female; age range, 3-31 years; median age, 9.5) were conditioned with
a fludarabine-based protocol for stem cell transplantation without radiation. In vivo T-cell depletion was
accomplished with anti-thymocytic globulin or Campath-1H (alemtuzumab). Graft-versus-host disease pro-
phylaxis consisted of low-dose cyclosporine alone. Eight transplantations were carried out for 7 patients using
bone marrow, peripheral blood, and/or cord blood as sources of stem cells. All patients received transplants
from HLA-A, -B, -C, and -DR matched donors, 5 from family members and 2 from matched unrelated donors.
One patient did not engraft her first matched unrelated donor and underwent a second transplantation from
another matched unrelated donor, after which she engrafted well. All 7 patients are alive and well, fully
reconstituted with donor cells, and with 100% performance status. In conclusion, fludarabine-based prepar-
ative protocols are well tolerated, facilitate rapid engraftment with minimal toxicity, and should be considered
an essential component of choice for patients with Fanconi anemia.
© 2006 American Society for Blood and Marrow Transplantation
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Fanconi anemia is an autosomal recessive disor-
er associated with congenital malformations, pro-
ressive marrow failure, and predisposition to acute
yelogenous leukemia (AML) and other malignan-
ies [1]. The syndrome is deﬁned by genomic insta-
ility and cellular hypersensitivity to DNA cross-
inking agents [2,3]. This hypersensitivity serves as
diagnostic test (using agents such as diepoxybu-
ane) and allows diagnosis of Fanconi anemia in
ases of subtle clinical features or no detectable con-
enital abnormalities [4]. Complementation studies
ave shown that there are 8 separate Fanconi ane- [
12ia complementation groups, and the genes respon-
ible for the defects in each group (A through G
ncluding D1 and D2) have been identiﬁed [5,6].
Stem cell transplantation (SCT) is the treatment
f choice for Fanconi anemia patients with severe
ematologic manifestations. Unfortunately, most
robably due to their high chromosomal fragility,
anconi anemia patients are very sensitive to conven-
ional conditioning protocols. Since the early 1980s,
hen it was demonstrated by the Paris group [7,8],
hemotherapy, especially alkylating agents and ioniz-
ng radiation, has been associated with a high inci-
ence of transplantation-related toxicity and mortality
9]. Over the years, many transplantation centers have
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Fludarabine-Based Protocols for Fanconi Anemia Patients 713sed radiation as an integral part of conditioning to
idestep the use of chemotherapy. However, radia-
ion is also associated with short- and long-term
oxicities and possibly with an increased risk of
econdary leukemia, to which Fanconi anemia pa-
ients are especially prone [10].
Reduced intensity conditioning (RIC) for SCT
ioneered at our center for the treatment of malignant
nd nonmalignant disorders [11] and in other centers
or high-risk patients with hematologic malignancies
12] constitutes a safer approach for hematologic re-
onstitution. These regimens are based on RIC that
ocuses on a window of immunosuppression for pre-
ention of rejection of donor stem cells, thereby im-
roving immediate and long-term transplantation
utcomes by preventing or minimizing procedure-
elated toxicity and mortality. The well-known advan-
ages of RIC based on cumulative experience in pa-
ients with malignant diseases are related to patients’
eneral feeling of well-being throughout the proce-
ure, independence from hyperalimentation, and low
ncidence of common immediate complications such
s mucositis and fever due to intercurrent infections
ecause of a shorter or no period of agranulocytosis
nd platelet dependence, and lesser risk of severe
eno-occlusive disease of the liver, interstitial pneu-
onitis, and multiorgan failure resulting from combi-
ation of some or all of the above. The main compo-
ent of most of these new conditioning regimens is
udarabine, a potent yet well-tolerated immunosup-
ressive agent [11,12].
With the expanding use of RIC for patients with
alignant diseases, it seemed reasonable to apply a
imilar conditioning for nonmalignant diseases, par-
icularly in patients known to be highly sensitive to
hemotherapy or ionizing radiation, such as those
ith Fanconi anemia. Over the past few years, after
ur initial report [13], the use of ﬂudarabine-based
egimens for transplantation in patients with Fanconi
nemia has become well established [14-21], and as-
ects are currently being raised regarding the use of
ord blood as the source of stem cells [15,16], T-cell–
able 1. Characteristics of Patients Who Underwent Fully Matched RI
UPN
Age
(y)
Organ
Abnormal Recipient Donor
114 10 No F M
202 12 Yes F F
420 10 Yes F F
535 31 Yes F F
548 3 No F F
548a 3 No F M
698 9 Yes M M
853 9 No F Fanemia; BM, bone marrow; PB, peripheral blood; CB, cord blood.epleted versus non–T-cell–depleted graft [17-19], or
he relevance of including radiation in the preparative
egimen [19-21]
Seven years ago, we published our ﬁrst case of
udarabine-based RIC in a Fanconi anemia patient
13]. In this report, we summarize our cumulative
xperience in transplanting patients with Fanconi ane-
ia from fully matched related or unrelated donors,
sing ﬂudarabine-based conditioning regimens.
ETHODS
Seven patients with Fanconi anemia (1 male and 6
emale; age range, 3-31 years; median age, 9.5 years)
nderwent 8 SCT procedures. Four patients had or-
an malformations and marrow failure (Table 1). Per-
entages of marrow blasts at the time of transplanta-
ion are listed in Table 1. Four patients had aplastic
nemia, 1 patient (who underwent 2 transplantations)
ad myelodysplastic syndrome, and 2 demonstrated
ransformation to AML. These 2 patients developed
ML features shortly before, did not receive any an-
ileukemia treatment, and were sent immediately for
ransplantation. Six patients received transfusions be-
ore transplantation. Of these, 5 received 10 U of
acked red blood cells and 1 (UPN 1202) was heavily
retransfused with 40 U of packed red blood cells
efore transplantation. All patients received andro-
ens at the period between diagnosis and admission
or transplantation. Karnofsky performance status
cores ranged from 90 to 100. Patients were referred
o the Hadassah University Hospital for SCT between
ovember 1996 and September 2003. Each partici-
ant signed an approved informed consent form and
he protocol was approved by the institutional review
oard. All patients received transplants from HLA-A,
B, -C and high-resolution DRB1 fully matched do-
ors; for patients who received transplants from un-
elated donors, high-resolution DQ was also tested.
ive patients received transplants from family mem-
ers, and 2 from matched unrelated donors (MUDs;
Fludarabine-Based Conditioning Regimens*
onor/Recipient
Relationship
Hematologic Status and
Marrow Blasts (%) at
Transplantation
Stem Cell
Source
Cousin AML (20%) BM
Sibling AA (0%) CB
Mother AA (0%) PB
Sibling AML (20%) PB
Unrelated MDS (18%) BM
Unrelated MDS (18%) BM
Unrelated AA (0%) BM
Sibling AA (0%) BM  CBC With
D
UPN indicates unique patient number; F, female; M, male; AML, acute-myeloid leukemia; MDS, myelodysplastic syndrome; AA, aplastic
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M. Bitan et al.714ncluding 1 patient who underwent 2 procedures from
ifferent MUDs; Table 1).
Pretransplantation conditioning of all patients
ontained ﬂudarabine plus other drugs, as indicated in
able 2. Five donors underwent bone marrow-derived
tem cell harvesting in the operating room under full
nesthesia on the day of transplantation. Two donors
ere injected subcutaneously with granulocyte colony-
timulating factor (G-Neupogen; Amgen AG, Lu-
erne, Switzerland), 5 g/kg twice daily for 5 days,
nd mobilized peripheral blood stem cells were col-
ected on days 5 and 6. Two donors donated cord
lood stem cells and 1 of these also donated bone
arrow-derived stem cells (this donor is also among
he 5 bone marrow donors mentioned above). Details
f the inocula are presented in Table 3.
Before transplantation, all patients received tri-
ethoprim-sulfamethoxazole (10 mg · kg1 · d1) on
able 2. Pretransplantation Conditioning Regimens Based on
ludarabine for Transplantation of Fanconi Anemia Patients*
Conditioning
Procedures,
n
UPNs of Patients
Transplanted
with this
Protocol
V fludarabine 30
mg · m2 · d1  6 d; IV
cyclophosphamide 5
mg · kg1 · d1  2 d; IV
antithymocytic globulin† 10
mg · kg1 · d1  4 d
5 1114, 1202, 1420,
1535, 1548
V fludarabine 30
mg · m2 · d1  6 d; IV
busulfex 3.2 mg · kg1 · d1
 2 d, alemtuzumab 5, 10,
20, 40 mg SC on days 4
to 1
1 1548a
V fludarabine 30
mg · m2 · d1  6 d; IV
cyclophosphamide 5
mg · kg1 · d1  2 d; IV
busulfex 3.2mg/kg/day 
2 d; antithymocytic
globulin† 10 mg · kg1 · d1
 4 d
1 1698
V fludarabine 30
mg · m2 · d1  6 d; IV
cyclophosphamide 5
mg · kg1 · d1  1 d; IV
busulfex 3.2 mg · kg1 · d1
 2d; antithymocytic
globulin†, 10
mg · kg1 · d1  4 d
1 1853‡
otal procedures 8
IV indicates intravenous; SC, subcutaneous; UPN, unique patient
number.
From Fresenius (Grafelﬁng, Germany).
This patient received only 1 dose of cyclophosphamide due to
kidney dysfunction that developed in the days of conditioning.
he dysfunction resolved spontaneously couple of days thereafter.ays 8 to 2, acyclovir (500 mg/m2 3 times daily) Ta U
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Fludarabine-Based Protocols for Fanconi Anemia Patients 715rom day 8 to day 100, and allopurinol (300 mg/d)
n days 8 to 1. Administration of trimethoprim-
ulfamethoxazole twice weekly was resumed after re-
overy from neutropenia as a preventive measure
gainst Pneumocystis carinii infection. Graft-versus-
ost disease (GVHD) prophylaxis consisted of low-
ose cyclosporine (CSA) 3 mg/kg intravenously daily
n 2 divided doses starting on day 4. Once patients
ere mobile, CSA was administered orally. CSA dos-
ge was tapered during the ﬁfth or sixth month after
ransplantation according to chimeric status and evi-
ence of GVHD.
Neutropenic patients with culture-negative fever
eceived a combination of gentamicin, cefazolin, and
ezlocillin or piperacillin as a ﬁrst-line antibiotic pro-
ocol. Persisting fever was treated with amikacin and
azocin as a second-line protocol, and meropenem
nd vancomycin were used as a third-line protocol. In
ases of persistent fever that did not respond to anti-
iotic therapy within 5 days, amphotericin B (1 mg/kg
very other day) was added until the neutropenia re-
olved.
As of day 8, patients were monitored with a
NA polymerase chain reaction (PCR) test to detect
ytomegalovirus; later in the study period, when pp65
ntigenemia was introduced, this test was carried out
n a weekly basis. Two consecutive positive PCR results
r 1 documented antigenemia test with 1 cell positive
or pp65 served as an indication for replacing acyclovir
ith ganciclovir, 10 mg · kg1 · d1, until 2 negative
ests were obtained. Patients were treated with reverse
solation in rooms equipped with HEPA ﬁlters, and
hey received a regular diet. Additional supportive
easures, such as parenteral nutrition and blood com-
onent transfusions, were administered as necessary.
Acute and chronic GVHD were graded according
o criteria of Glucksberg et al [22]. Immediately after
he appearance of GVHD symptoms, intravenous
ethylprednisolone (2 mg/kg) and CSA were admin-
stered.
To assess engraftment, degree of chimerism, min-
mal residual disease, and early relapse, patients were
onitored at regular intervals by cytogenetic analysis,
onor- and host-speciﬁc DNA markers using male
nd female amelogenin gene PCR bands [23], and by
ariable number of tandem repeats/PCR assay [24].
ESULTS
All 7 patients were alive, well, and free of disease
9 to 101 months after transplantation. Seven patients
nderwent 8 allogeneic transplantation procedures
patient UPN 1548 received 2 transplants). RIC pro-
ocols were well tolerated. No severe hepatic veno-
cclusive disease (VOD) occurred in any patient. Mild
o moderate VOD was documented in 3 of 8 proce- tures and subsided with hydration (3000-4000
L · m2 · d1) combined with diuresis. No VOD ep-
sode caused further complications. All patients devel-
ped fever, with a median of 1 febrile episode (range,
-2) and a median of 6 febrile days (range, 3-14). Oral
ucositis was mild, and only 50% of patients required
upplemental parenteral nutrition for a median of 11
ays (range, 9-26). During the other 4 procedures,
atients were maintained on normal oral intake.
ngraftment
Six patients displayed evidence of stable 3-lineage
ngraftment. One patient (UPN 1548), a recipient of
MUD transplant, exhibited immune-mediated graft
ejection and immediately underwent a second trans-
lantation from another MUD; engraftment of this
onation occurred 13 days later.
The lowest white blood cell count was .1  109/L
range, .1-.2). Recovery of absolute neutrophil
ounts .5 and 1.0  109/L took 11-40 days (me-
ian, 20.5) and 12-40 days (median, 27.5), respec-
ively. The lowest platelet count was 7  109/L
range, 2-10). Intervals to platelet recovery (20 and
50  109/L) were 9-56 days (median, 19) and 11-67
ays (median, 35), respectively. Median number of
acked red cell transfusions was 4.5 U (range, 2-14)
nd median platelet transfusions from single and ran-
om donors was 13.5 U (range, 2-107).
ransplant-Related Morbidity and Mortality
There was no severe transplant-related toxicity
nd no mortality.
Transplant-related complications occurred in the
ourse of 2 of 8 (25%) procedures and consisted of 1
ase of brain abscess and 1 case of acute renal failure.
n the case of brain abscess (UPN 1535), the present-
ng sign was grand-mal seizure followed by fever.
omputed tomography showed a focal lesion in the
eft parieto-occipital hemisphere of the cerebrum.
umber puncture done after excluding hazardous
igh intracranial pressure and/or pending herniation
evealed a high protein level and a large number of
nﬂammatory cells. Culture of this specimen grew
spergillus. The pathologic lesion was then stereotac-
ically biopsied and showed a granulomatotic process
ompatible with Aspergillus infection. The patient was
reated with intravenous liposomal amphotericin, with
ood response. In the case of renal failure (UPN
114), this patient did not have renal problems before
ransplantation and was treated by hydration (3000-
000 mL · m2 · d1) and holding any possible neph-
otoxic drug (acyclovir and CSA) until renal function
as improved. Both conditions subsided without any
ong-term deﬁcit.
Infectious episodes that occurred from the day ofransplantation and up to 1 year after transplantation
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M. Bitan et al.716re presented in Table 4. No reactivation of cytomeg-
lovirus was seen in patients during their hospital stay.
ll patients were discharged for continuing outpatient
reatment after a median hospital stay of 48.5 days
range, 23-77). They continue to be followed on an
mbulatory basis. The median follow-up period to
ate is 49.5 months (range, 14-96).
ncidence and Severity of GVHD
No patient developed severe (grade III-IV) acute
VHD. Two patients developed mild (grade II)
cute GVHD, which later progressed to mild chronic
VHD. The ﬁrst patient (UPN 1535) had grade II
kin involvement that started at day 62 after trans-
lantation. It was treated by CSA and corticosteroids
ut progressed to extensive chronic GVHD with skin,
outh leukoplakia, and liver involvements. After cor-
icosteroidal treatment, all involved areas stabilized
nd improved but did not completely resolve. The
ther patient (UPN 1698) also developed grade II skin
nvolvement that started on day 28 after transplan-
ation. As with the ﬁrst patient, he was treated with
ombination of CSA and corticosteroids but pro-
ressed to limited chronic GVHD that affected his
kin. This was treated with corticosteroids and re-
olved completely. One patient (UPN 1202) devel-
ped limited de novo chronic GVHD with liver in-
olvement. She was treated with corticosteroids and
ad a good response, with complete resolution of the
vent.
ISCUSSION
Fanconi anemia is a systemic disease that is fre-
uently associated with congenital malformations, se-
ere progressive stem cell failure, and high incidence
f leukemia. Allogeneic SCT is the only known cur-
tive procedure for hematologic abnormalities. To
ircumvent short- and long-term procedure-related
able 4. Infectious Episodes in Fanconi Anemia Patients up to One Yea
UPN
Days After
Transplantation
Site of
Infection
114 None NR
202 None NR
420 None NR
535 10 Brain
127 Palate
548 7 Blood
548a 6 Blood
698 60 Throat
853 None NR
UPN indicates unique patient number; None, no infection occurre
of infection.
See Methods section.isks, particularly in patients with Fanconi anemia, it is smperative to minimize or prevent peri- and post-
ransplantation morbidity resulting from alkylating
hemotherapy and ionizing radiations. Nevertheless,
any yet unknown parameters may play a role in the
urvival of such patients. Thus, it seems that Fanconi
nemia patients reconstituted with matched sibling-
erived stem cells are doing much better in terms of
urvival after transplantation compared with patients
ngrafted from alternative, unrelated donors [25].
ased on our ﬁrst reported case [13], it seemed that
udarabine-based protocols may be particularly suit-
ble for improving dramatically the outcome of Fan-
oni anemia patients in need of SCT. As anticipated,
he ﬂudarabine-based transplantation procedures used
ppeared to be much better tolerated and all patients
re alive with excellent performance status. This holds
rue regardless of the recipient-donor relations. The
roup of patients presented is somewhat heteroge-
eous in terms of conditioning regimens, but the het-
rogeneity of the protocols, with ﬂudarabine as the
ingle unchanged medication, emphasizes its pivotal
ole in ensuring a safe engraftment in this cohort of
atients. Only 1 patient with a MUD transplant re-
ected the graft but her second transplantation from
nother MUD, after additional conditioning, was suc-
essful. She did not undergo heavy pretransfusion be-
ore the ﬁrst transplantation, had 18% blasts in bone
arrow with myelodysplastic syndrome features, and
as treated with CSA 3 mg/kg from day 4, which
as continued after transplantation as the sole anti-
VHD prophylaxis after transplantation of bone mar-
ow-derived stem cells. A safe and uneventful outcome
fter the second transplantation is additional evidence
f the excellent tolerability of the ﬁrst ﬂudarabine-
ased transplantation procedure. The second recipi-
nt of SCT from a MUD had successful outcome after
sing the modiﬁed RIC protocol that was used for the
rst MUD recipient.
In contrast to previously used regimens [26], the
Transplantation*
ame of Causative Strain Treatment
NR
NR
NR
illus Liposomal amphotericin
s simplex Acyclovir
lococcus coagulase negative Antibiotic protocols†
monas aeruginosa Antibiotic protocols†
a albicans Fluconazole
NR
1 year after transplantation; NR, no relevance due to no occurrencer After
N
NR
NR
NR
Asperg
Herpe
Staphy
Pseudo
Candid
NR
d untiluccessful protocols described in this report, which
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Fludarabine-Based Protocols for Fanconi Anemia Patients 717voided the use of radiation and/or high-dose alkylat-
ng agents, may decrease not only the immediate risks
f transplantation but also the long-term risk of sec-
ndary malignancies caused by chromosomal instabil-
ty. Neither HLA alloimmunization, due to multiple
ransfusions of blood products, nor previous treatment
ith androgens [27] compromised engraftment in our
atients.
As in the use of RIC regimens in patients without
anconi anemia, all patients experienced a relatively
asy and uneventful course of hospitalization that was
arked by a low incidence of fever, minimal require-
ent for hyperalimentation, and a low incidence of
cute GVHD. However, time to engraftment was
ildly prolonged than expected after receiving RIC. A
ossible explanation is that patients with Fanconi ane-
ia do not tolerate standard conditioning regimens
7,8], so RIC may be more harmful to bone marrow
han in patients without Fanconi anemia. Therefore,
lthough intensity was decreased, the protocols de-
cribed in this study may have caused the relatively
ate engraftment. This is emphasized by the lack of
orrelation between duration of engraftment in each
atient and stem cell source, stem cell dose, and pre-
arative therapy.
Zanis-Neto et al [28] reported that patients with
anconi anemia can tolerate cyclophosphamide at
oses up to 80 mg/kg, which is much higher than the
0-mg/kg dose given in our study. However, in our
tudy cyclophosphamide was only part of the condi-
ioning regimen, which included 1 more agent,
hereas cyclophosphamide was the only chemother-
py used in the study by Zanis-Neto et al.
One patient developed acute GVHD with an acute
nfectious event of brain abscess during transplanta-
ion hospitalization. This led us to decrease dramati-
ally the immune-suppression medications and may
ave led to the development of acute GVHD. Because
atients with Fanconi anemia without evidence of
ML or other cancer at time of transplantation do not
eed induction of graft-versus-leukemia or graft-ver-
us-malignancy effects that may be associated with
VHD, and because GVHD carries the risk of sec-
ndary head and neck carcinomas developing over the
ong term [29], minimizing the incidence of GVHD in
atients with Fanconi anemia seems desirable. Hence,
sing some degree of in vivo T-cell depletion of donor
lloreactive T cells, in addition to host alloreactive
ymphocytes by anti-thymocytic globulin or alemtu-
umab, as used in the present cohort, seems justiﬁed.
oreover, the use of intravenous busulfan, a myelo-
blative agent with limited toxicity to mature lympho-
ytes, further keep some host T cells, potentially with
eto capacity, and thus decreases even more the risk of
VHD in this cohort of patients [30]. However, ex-
essive T-cell depletion after grafting should be con-
idered cautiously or avoided due to the increased riskf allograft rejection because T cells play a signiﬁcant
ole in facilitation of engraftment, especially in recip-
ents who are conditioned with a nonmyeloablative
egimen.
In conclusion, the present results based on a small
ohort of patients support the use of ﬂudarabine-
ased RIC in preparation for SCT for patients with
anconi anemia. However, larger cohorts of patients
hould be evaluated for longer follow-up periods to
eﬁne the optimal RIC for patients with Fanconi
nemia in need of SCT.
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